Last update 01 Nov 2024

GC-012F

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
BCMA-Antigen X bispecific CAR-T cells, BCMA/CD19 dual-targeting CAR-T therapy
+ [3]
Mechanism
BCMA inhibitors(B-cell maturation protein inhibitors), CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors)
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Systemic Lupus ErythematosusPhase 2
CN
15 Aug 2024
Plasma cell myeloma refractoryPhase 2
US
20 Jul 2023
Relapse multiple myelomaPhase 2
US
20 Jul 2023
Chromosome DisordersPhase 2
CN
01 Dec 2021
Multiple MyelomaPhase 2
CN
28 Jun 2021
BCMA Positive Multiple MyelomaPhase 2
CN
16 Jan 2020
Myasthenia GravisPhase 1
CN
01 Dec 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Early Phase 1
12
(eujwqulyzl) = included lymphocytopenia(11/12), neutropenia (11/12), leukopenia (10/12), and thrombocytopenia (3/12) agufvtwunc (qbllwymlro )
Positive
14 May 2024
Phase 1
Multiple Myeloma
First line
...
22
induction therapy + GC012F
ejsqdytnxm(fdufzvhaqx) = qmtivsmiek erpzjacqfv (frmjdlqaxz )
Positive
14 May 2024
Phase 1/2
22
(lnoposewiz) = ajclqwqden kneofawogu (djvbvdudue )
Positive
11 Dec 2023
Phase 1
19
(cdpiqqpvyc) = ckbnebrgob wkbozrkffr (iwkjljyaox )
Positive
27 Sep 2023
Early Phase 1
29
(tauvsihlfy) = CRS 86.2%, ≤grade 2 (n=23, 79.3%) and 2 (6.9%) pts were grade 3. No ICANS was observed yzadlsvwem (nbmjtlvodm )
Positive
31 May 2023
Early Phase 1
B-cell lymphoma refractory
Third line
CD19 | BCMA
9
(kwmiioayqp) = All TEAEs were resolved after treatment with standard of care and supportive care. vgfyznzylr (ajruwmoyaj )
Positive
31 May 2023
Phase 1
13
(zaadlpdsoi) = darhcapdhp wdyeidwsmk (ztnxxscxwr )
Positive
15 Nov 2022
Early Phase 1
28
(eipubqsxyf) = CAR-T geometric mean AUC0-28 for DL1, DL2 and DL3 were 468863, 631540 and 581620 copies/μg DNA×day, respectively. wujqoahvsf (kqwghzdzwm )
Positive
02 Jun 2022
Not Applicable
28
becuvwbzev(zbmeizuoju) = hdmptepogl hzcycemluy (fnpebwhcar )
-
26 May 2022
Phase 1
19
yajsphplpw(ilielbaiae) = dlkijhwtbv ntosnktrrw (yofdnxevgu )
-
09 Jun 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free